In conclusion, we reported a remarkable instability of HER2 expression from primary breast cancer to residual disease in a large cohort of patients undergoing neoadjuvant chemotherapy, with HER2-low-positive expression instability being the major driver of such phenomenon. This evidence concerns the gene ERBB2 and breast carcinoma.